ATE307208T1 - Pseudomonas exotoxin-a-ähnliche chimerische immunogene - Google Patents

Pseudomonas exotoxin-a-ähnliche chimerische immunogene

Info

Publication number
ATE307208T1
ATE307208T1 AT98935604T AT98935604T ATE307208T1 AT E307208 T1 ATE307208 T1 AT E307208T1 AT 98935604 T AT98935604 T AT 98935604T AT 98935604 T AT98935604 T AT 98935604T AT E307208 T1 ATE307208 T1 AT E307208T1
Authority
AT
Austria
Prior art keywords
pseudomonas exotoxin
chimeric immunogens
immunogens
chimeric
exotoxin
Prior art date
Application number
AT98935604T
Other languages
English (en)
Inventor
David J Fitzgerald
Original Assignee
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv filed Critical Us Gov Health & Human Serv
Application granted granted Critical
Publication of ATE307208T1 publication Critical patent/ATE307208T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C07K16/1145—Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT98935604T 1997-07-11 1998-07-10 Pseudomonas exotoxin-a-ähnliche chimerische immunogene ATE307208T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5237597P 1997-07-11 1997-07-11
PCT/US1998/014341 WO1999002713A1 (en) 1997-07-11 1998-07-10 Pseudomonas exotoxin a-like chimeric immunogens

Publications (1)

Publication Number Publication Date
ATE307208T1 true ATE307208T1 (de) 2005-11-15

Family

ID=21977213

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98935604T ATE307208T1 (de) 1997-07-11 1998-07-10 Pseudomonas exotoxin-a-ähnliche chimerische immunogene

Country Status (10)

Country Link
US (1) US8092809B2 (de)
EP (1) EP1000163B1 (de)
JP (2) JP2001510683A (de)
AT (1) ATE307208T1 (de)
AU (1) AU731703B2 (de)
CA (1) CA2295971C (de)
DE (1) DE69831951T2 (de)
DK (1) DK1000163T3 (de)
ES (1) ES2249838T3 (de)
WO (1) WO1999002713A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1078988A1 (de) * 1999-08-27 2001-02-28 Academia Sinica Pseudomonas Fusionsprotein-Impstoff
US6838553B1 (en) * 1999-10-05 2005-01-04 Academia Sinica Peptide repeat immunogens
EP1242122B1 (de) * 1999-10-22 2009-09-30 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Proteine-abgabe durch polare epithelzellen schichte
TWI293957B (en) * 2004-07-21 2008-03-01 Healthbanks Biotech Co Ltd A superantigen fusion protein and the use thereof
US7964200B2 (en) 2005-05-18 2011-06-21 Children's Hospital & Research Center At Oakland Methods and compositions for immunizing against Chlamydia infection
US20090203884A1 (en) * 2008-01-31 2009-08-13 Healthbanks Biotech Co., Ltd. Chimeric hiv fusion proteins as vaccines
US11246915B2 (en) 2010-09-15 2022-02-15 Applied Molecular Transport Inc. Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
US8932586B2 (en) 2011-09-06 2015-01-13 Intrexon Corporation Modified forms of Pseudomonas exotoxin A
CN109608550B (zh) * 2012-12-05 2020-09-11 生控基因疫苗股份有限公司 用作诱发抗原特异性t细胞反应的免疫原性增强剂的融合蛋白
US9861681B2 (en) 2013-04-18 2018-01-09 The United States of America as represented by the Secretary of the Army, on behalf of the United States Army Medical Research Institute of Infectious Diseases Therapeutic compositions for neutralizing type I interferons, and methods of use
CA2985381C (en) * 2015-06-01 2020-03-24 Reber Genetics Co., Ltd. Vaccine compositions against porcine reproductive and respiratory syndrome and porcine circovirus associated diseases
PL3762009T3 (pl) 2018-03-08 2022-09-12 Applied Molecular Transport Inc. Pochodzące z toksyny konstrukty dostarczające do dostarczania doustnego
SG11202104734YA (en) 2018-11-07 2021-06-29 Applied Molecular Transport Inc Cholix-derived carriers for oral delivery of heterologous payload

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4545985A (en) * 1984-01-26 1985-10-08 The United States Of America As Represented By The Secretary, Dept. Of Health And Human Services Pseudomonas exotoxin conjugate immunotoxins
US6022950A (en) * 1984-06-07 2000-02-08 Seragen, Inc. Hybrid molecules having translocation region and cell-binding region
US5668255A (en) * 1984-06-07 1997-09-16 Seragen, Inc. Hybrid molecules having translocation region and cell-binding region
CA1289880C (en) * 1985-12-06 1991-10-01 Jeffrey L. Winkelhake Anti-human ovarian cancer immunotoxins and methods of use thereof
US5082927A (en) * 1986-09-24 1992-01-21 The United States Of America As Represented By The Department Of Health And Human Services Selectively cytotoxic IL-4-PE40 fusion protein
US6051405A (en) * 1986-09-24 2000-04-18 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Constructs encoding recombinant antibody-toxin fusion proteins
US4892827A (en) * 1986-09-24 1990-01-09 The United States Of America As Represented By The Department Of Health And Human Services Recombinant pseudomonas exotoxins: construction of an active immunotoxin with low side effects
US5206353A (en) * 1988-07-23 1993-04-27 The United States Of America As Represented By The Department Of Health And Human Services CD-4/cytotoxic gene fusions
CA1340530C (en) * 1989-04-28 1999-05-04 Kok Kheong Lee Synthetic pseudomonas aeruginosa pilin peptide and related vaccines and diagnostics
US5980896A (en) * 1989-06-30 1999-11-09 Bristol-Myers Squibb Company Antibodies reactive with human carcinomas
US6020145A (en) * 1989-06-30 2000-02-01 Bristol-Myers Squibb Company Methods for determining the presence of carcinoma using the antigen binding region of monoclonal antibody BR96
AU657087B2 (en) * 1989-12-22 1995-03-02 Seragen Incorporated Hybrid molecules having translocation region and cell-binding region
US5458878A (en) * 1990-01-02 1995-10-17 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services P. exotoxin fusio proteins have COOHG220101al alterations which increase cytotoxicity
JP2665827B2 (ja) * 1990-05-11 1997-10-22 アメリカ合衆国 低―動物毒性と高殺細胞活性の改良シュードモナス外毒素
US5608039A (en) * 1990-10-12 1997-03-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Single chain B3 antibody fusion proteins and their uses
US6099842A (en) * 1990-12-03 2000-08-08 The United States Of America As Represented By The Department Of Health And Human Services Recombinant immunotoxin composed of a single chain antibody reacting with the human transferrin receptor and diptheria toxin
US5328984A (en) * 1991-03-04 1994-07-12 The United States As Represented By The Department Of Health & Human Services Recombinant chimeric proteins deliverable across cellular membranes into cytosol of target cells
US5190873A (en) * 1991-06-21 1993-03-02 California Institute Of Biological Research Hybrid tryptophan aporepressor containing ligand binding sites
US5621083A (en) * 1991-11-04 1997-04-15 Xoma Corporation Immunotoxins comprising ribosome-inactivating proteins
US5935580A (en) * 1992-04-21 1999-08-10 Institut Pasteur Recombinant mutants for inducing specific immune responses
CA2136724A1 (en) * 1992-06-18 1993-12-23 Ira H. Pastan Recombinant pseudomonas exotoxin with increased activity
US6303120B1 (en) * 1994-03-15 2001-10-16 Memorial Sloan-Kettering Institute For Cancer Research Synthesis of glycoconjugates of the lewis y epitope and uses thereof
US5635599A (en) * 1994-04-08 1997-06-03 The United States Of America As Represented By The Department Of Health And Human Services Fusion proteins comprising circularly permuted ligands
DK0759944T3 (da) 1994-05-13 2001-11-26 Biovation Ltd Forbedringer af og relateret til peptidfremføring
US5573916A (en) * 1994-05-19 1996-11-12 Coretech, Inc. Immunogenic constructs comprising b-cell and t-cell epitopes on common carrier
DE69521331T2 (de) * 1994-11-01 2001-09-20 Winfried Wels Nukleinsäure-einbringungssystem
US5843882A (en) * 1995-04-27 1998-12-01 The United States Of America As Represented By The Department Of Health And Human Services Antiviral proteins and peptides
US5980895A (en) * 1995-10-13 1999-11-09 The United States Of America As Represented By The Department Of Health And Human Services Immunotoxin containing a disulfide-stabilized antibody fragment joined to a Pseudomonas exotoxin that does not require proteolytic activation
IL116559A (en) * 1995-11-17 2005-11-20 Yissum Res Dev Co Chimeric protein consisting of a bacterial toxin and a myelin basic protein sequence
WO1997025068A2 (en) * 1996-01-05 1997-07-17 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Mesothelin antigen and methods and kits for targeting it
US6426075B1 (en) * 1996-11-06 2002-07-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Protease-activatable pseudomonas exotoxin A-like proproteins
US6086900A (en) * 1997-03-26 2000-07-11 Board Of Regents, The University Of Texas Systems Methods and compositions for using membrane-penetrating proteins to carry materials across cell membranes
US20030054012A1 (en) * 2000-05-12 2003-03-20 Fitzgerald David J. Pseudomonas exotoxin a-like chimeric immunogens for eliciting a secretory iga-mediated immune response
US6140066A (en) * 1998-03-24 2000-10-31 Lorberboum-Galski; Haya Methods of cancer diagnosis using a chimeric toxin
US6090388A (en) * 1998-06-20 2000-07-18 United Biomedical Inc. Peptide composition for prevention and treatment of HIV infection and immune disorders
EP1242122B1 (de) * 1999-10-22 2009-09-30 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Proteine-abgabe durch polare epithelzellen schichte
EP1224290B1 (de) * 1999-10-22 2006-06-28 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Disulfidkonjugierte zellgifte und verfahren zur ihrer herstellung und verwendung
US6783761B2 (en) * 2000-05-05 2004-08-31 Aphton Corporation Chimeric peptide immunogens
DK1379550T3 (da) * 2000-12-21 2009-07-06 Us Gov Health & Human Serv Et kimært protein omfattende non-toxisk pseudomonas exotoxin A og en type IV pilin sekvenser
EP1549144A4 (de) * 2002-10-04 2010-01-06 Univ California Verfahren zur behandlung von krebs durch hemmung der wnt-signalleitung
WO2004033657A2 (en) * 2002-10-07 2004-04-22 Antigenics, Inc. Heat shock protein binding fragments of cd91, and uses thereof
US7335361B2 (en) * 2003-06-09 2008-02-26 Animal Technology Institute Taiwan Fusion antigen used as vaccine
WO2006041906A2 (en) * 2004-10-04 2006-04-20 Trinity Biosystems, Inc. Methods and compositions for immunizing against pseudomonas infection
US8877714B2 (en) * 2005-06-14 2014-11-04 Raptor Pharmaceutical Inc. Compositions comprising receptor-associated protein (RAP) variants specific for LRP2 and uses thereof
WO2008118013A2 (en) * 2007-03-23 2008-10-02 To-Bbb Holding B.V. Targeted intracellular delivery of antiviral agents
US20100143920A1 (en) * 2007-04-06 2010-06-10 The Trustees Of The University Of Pennsylvania Surfactant Protein D is a Biomarker for Steroid Responsiveness in Asthma and Chronic Obstructive Pulmonary Disease

Also Published As

Publication number Publication date
US8092809B2 (en) 2012-01-10
ES2249838T3 (es) 2006-04-01
EP1000163A1 (de) 2000-05-17
DK1000163T3 (da) 2006-02-06
DE69831951T2 (de) 2006-07-27
JP2001510683A (ja) 2001-08-07
WO1999002713A1 (en) 1999-01-21
US20090269368A1 (en) 2009-10-29
EP1000163B1 (de) 2005-10-19
AU8481398A (en) 1999-02-08
AU731703B2 (en) 2001-04-05
CA2295971A1 (en) 1999-01-21
CA2295971C (en) 2011-02-08
DE69831951D1 (de) 2006-03-02
JP2009079068A (ja) 2009-04-16

Similar Documents

Publication Publication Date Title
DK1000163T3 (da) Pseudomonas-exotoksin A-lignende kimære immunogener
NO994998L (no) Fusjonsproteiner
EP1208085A4 (de) Benzanilide als öffner des kaliumkanals
WO2002081646A3 (en) Epitope sequences
WO1999051275A3 (en) Mesenchymal stem cells as immunosuppressants
ATE377027T1 (de) Tetravalente antikörperkonstrukte
DK0854917T3 (da) Transgene ikke-humane dyr, som kan producere heterologe antistoffer
TR199700343A3 (tr) Titresimli blender.
GEP20105119B (en) Chimeric anti-cd20 antibody
NO990533D0 (no) GnRH-leukotoksin kimµrer
DE69737218D1 (de) Adjuvant für transkutane Immunisation
MY139523A (en) Ziprasidone composition and synthetic controls
DK0876398T3 (da) Induktion af immunrespons med ønskede determinanter
DE60042816D1 (de) T-helferzellen-epitope
ATE340863T1 (de) Pseudomonas exotoxin a-ähnliche chimerische immunogene zum auslösen einer sekretorischen iga- vermittelten immunantwort
WO2003009740A3 (en) Methods for treating or preventing sclerotic disorders using cd2-binding agents
ATE417112T1 (de) Steigerung der immunantwort unter verwendung von zielgerichteten molekülen
IL139832A0 (en) Therapeutic compositions that produce an immune response by altering the antigen
NO962125D0 (no) Anti-idiotypiske antistoffer som induserer en immunrespons mot epidermal vekstfaktorreseptor
DK0831881T3 (da) CETP til forøgelse af HDL-cholesterolniveau
WO1999016466A3 (en) Vaccine compositions and methods of enhancing vaccine efficacy
FI974091A7 (fi) Menetelmä maksusuoritteiden välittämiseksi Internet-verkossa
MX9804043A (es) Composiciones parasiticidas a base de polisiloxanos ciclicos.
DK1183044T3 (da) Adjuvanskombinationer til immunisering og vacciner
EP0606901A3 (de) Elektrophotographisches Gerät.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1000163

Country of ref document: EP